Gilead Sciences: Still Plenty of Growth Despite 'Stagnated' HepatitisC

Gilead Sciences: Still Plenty of Growth Despite 'Stagnated' Hepatitis–C For Gilead, the company's HCV launch in the U.S. has stagnated but there is still plenty of opportunity for ex-U.S. growth. As payors still won't let HCV patients flow through the … Continue reading